Jump to content
Powered by BIOPRO BW
  • BIOPRO BW
  • Healthcare industry
  • Project pages
    • MDR & IVDR
    • Innovation & Startups
Healthcare industry Logo

Main navigation

  • Start page Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close Close
  • Databases

    Databases

    Close Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • KyooBe Tech GmbH - 08/10/2020 Scheme of the patented pump and roll system (LEEI technology).

    Next generation vaccine production

    For decades, conventional inactivated vaccines have been produced by killing pathogens with toxic chemicals. However, this process often changes the surface structure of the pathogens to such an extent that the immune system is only able to induce a weak response. KyooBe Tech GmbH is offering a method that uses low-energy electrons to inactivate pathogens. Vaccines produced this way are much higher quality, making them safer and more effective.

    https://www.gesundheitsindustrie-bw.de/en/article/news/next-generation-vaccine-production
  • Press release - 21/08/2025

    Nanodroplets Could Speed Up the Search for New Medicine

    Until now, the early phase of drug discovery for the development of new therapeutics has been cost- and time-intensive. Researchers at KIT have developed a platform on which extremely miniaturized nanodroplets with a volume of 200 nanoliters per droplet and containing 300 cells per test can be arranged. This platform enables the researchers to synthesize and test thousands of therapeutic agents on the same chip, saving time and resources.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/nanodroplets-could-speed-search-new-medicine
  • Press release - 30/04/2026

    The white spot of inner ear research

    A new technique based on labelled sugar molecules is providing previously unknown insights into the inner ear. A study by the University of Konstanz and Charité-Universitätsmedizin Berlin shows that the cupula in the inner ear of zebrafish completely regenerates within approximately two months. These findings open up a new avenue for research into sudden hearing loss and acute disorders of the sense of balance.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/white-spot-inner-ear-research
  • Press release - 29/06/2026

    PFAS in medicines can often be replaced with alternatives

    Certain medicines contain compounds known as PFAS, which are causing increasing environmental harm due to their long-lasting effects. A report by the University of Freiburg, commissioned by the German Environment Agency, shows that many PFAS-based active ingredients used in medicines can be replaced by alternatives. Based on the findings of the report, doctors will in future be able to give preference to prescribing PFAS-free medicines.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/pfas-medicines-can-often-be-replaced-alternatives
  • Gene regulation as a starting point for cancer therapies - 02/12/2021 Schematische Darstellung der verschiedenen Stadien der Genexpression. Nukleinsäurestränge sind durch farbige Linien, Proteine durch farbige Ellipsen und die Methylierung durch kleine Kreise dargestellt.

    New investigation method for deciphering complex epigenetic networks

    The development and maintenance of uncontrolled cell division in tumours is often due to the unbalanced, complex interplay of regulatory epigenetic networks. Researchers at the Institute of Biochemistry and Technical Biochemistry in Stuttgart have developed a new screening system to identify essential components that can serve as targets for anticancer drugs.

    https://www.gesundheitsindustrie-bw.de/en/article/news/new-investigation-method-deciphering-complex-epigenetic-networks
  • Animal-free testing of chemicals and cosmetics - 07/05/2025 A histological section of human skin showing the different layers of the epidermis, including the keratinizing squamous epithelium

    Human reporter skin for visualsing skin reactions

    Before new cosmetics can be placed on the market, all ingredients must undergo rigorous testing for safety and efficacy. Dr. Anke Burger-Kentischer of the Fraunhofer IGB has long been at the forefront of animal-free research and has developed an innovative method to quickly and reliably test cosmetics and other chemicals without using animals. She was awarded the 2024 Hamburg Research Prize for her groundbreaking ‘reporter skin’ in vitro model.

    https://www.gesundheitsindustrie-bw.de/en/article/news/human-reporter-skin-visualsing-skin-reactions
  • Press release - 05/09/2025

    After EMBL: Umlaut.bio and its potential role in drug development

    Alumnus Bastian Linder discusses the origin of this start-up and how a tRNA mechanism is helping scientists understand the importance and use of various RNA modifications as they pertain to disease.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/after-embl-umlautbio-and-its-potential-role-drug-development
  • Press release - 29/07/2026

    ERC Synergy Grant has started

    The international research project MitoContact is dedicated to investigating how organelles within a cell communicate and interact with other cellular components. Kai Johnsson, Director at the Max Planck Institute for Medical Research, has received funding from the ERC for this project. The findings are expected to provide new insights into fundamental cellular processes and contribute to a better understanding of various diseases.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/erc-synergy-grant-has-started
  • Press release - 30/09/2026

    How cells pass on regulatory information

    A project funded by the Baden-Württemberg Stiftung at the Max Planck Institute of Immunobiology and Epigenetics in Freiburg is investigating the interplay between RNA modifications and epigenetic mechanisms during cell division – and its potential significance for treatment resistance in cancer.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-cells-pass-regulatory-information
  • Press release - 04/09/2025

    Rare bone tumors: Tailor-made mini-proteins switch off tumor drivers

    Chordomas are rare bone tumors for which there are no effective drugs. A research team from the DKFZ and the NCT Heidelberg has now developed a promising approach: Tailor-made mini-proteins specifically block the driver of tumor development. In the result, slowing the growth of chordoma cells in the laboratory and in a mouse model, while also revealing further molecular vulnerabilities of the tumor that could be addressed with approved drugs.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/rare-bone-tumors-tailor-made-mini-proteins-switch-tumor-drivers-1
  • Press release - 05/01/2024

    Prostate cancer: Newly-developed inhibitor shows massive potential

    More than 65,000 men fall ill with prostate cancer each year in Germany. Twelve thousand of them develop a treatment-resistant form which eventually ends in death. Now, a team of researchers from the Medical Faculty at the University of Freiburg has developed an active substance that might in future represent a new treatment option.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/prostate-cancer-newly-developed-inhibitor-shows-massive-potential
  • Press release - 18/02/2026

    New centre for cell research

    Technology impulse for the Lake Constance region: The new Single Cell Centre at the University of Konstanz offers technology and expertise to study cells individually and at high resolution – for applications in medical diagnostics, medication development and basic research at universities.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-centre-cell-research
  • Sustainable medical technology - 10/10/2024 Various plastic medical items such as gloves, tablet blisters, containers, syringes and a blood pressure monitor are arranged on a green background.

    Rethinking plastics in medical technology

    Good healthcare relies heavily on medical products made from plastic. However, the widespread use of synthetic materials, particularly disposable items, creates vast amounts of waste, depletes resources and leads to a substantial carbon footprint. To create more environmentally friendly plastic products in the future, substantial changes to production processes are essential.

    https://www.gesundheitsindustrie-bw.de/en/article/news/rethinking-plastics-medical-technology
  • Press release - 12/05/2026

    3D Microscopy: Laser Rotates Samples Contact-Free

    Until now, it has been technically nearly impossible to rotate highly sensitive samples in all directions under a microscope without making contact. Researchers at the KIT have developed a new laser-based technique that allows microscopic samples such as cells to be rotated contact-free in all three spatial directions. The laser creates tiny temperature differences in the liquid, which trigger gentle fluid flows that move the sample.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/3d-microscopy-laser-rotates-samples-contact-free
  • Gene regulation - 20/07/2021 Vor schwarzem Hintergrund ist ein gelb leuchtendes Chromosom zwischen blau gefärbten Chromosomen sichtbar.

    The many faces of the epigenetic regulator MOF

    Epigenetic modifications play a crucial role in coordinated gene transcription, and are required for a fertilised egg cell to be able to develop into an organism with different cell types. Dr. Asifa Akhtar from the Max Planck Institute of Immunobiology and Epigenetics in Freiburg has been studying the essential epigenetic regulator protein MOF for 20 years.

    https://www.gesundheitsindustrie-bw.de/en/article/news/die-vielen-gesichter-des-epigenetischen-regulators-mof
  • TGU Varimol - 24/07/2020 Das Bild zeigt zwei kleine braune Chemikalienfläschchen, die alle nötigen Reagenzien für ihre Anwendung für Kunden der Varimol enthalten.

    Click chemistry for new medical procedures

    Using a simple molecular click process, biochemists have been able to connect ring-shaped molecules with each other and couple therapeutically active substances to these molecules. Drugs can thus be specifically delivered to diseased cells and used for imaging processes or biosensors. The Stuttgart-based start-up Varimol is using this new technology to provide its customers with tailored applications that are as simple to use as a kit.

    https://www.gesundheitsindustrie-bw.de/en/article/news/click-chemistry-new-medical-procedures
  • Dossier - 02/12/2013 AI generated symbolic image of an RNA strand.

    RNA interference confidence is returning

    The 15-year history of RNA interference is not short on dramatic effects. It begins with the unexpected discovery and publication of the process of post-transcriptional gene silencing in 1998 for which Andrew Fire and Craig Mello were awarded the Nobel Prize in Physiology or Medicine just eight years after their discovery. In 2001 Thomas Tuschl succeeded in switching off genes in human cells with small synthetic pieces of RNA siRNA.

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/rna-interference-confidence-is-returning
  • Dossier - 23/01/2012 Microscope image of a motoneuron of the spinal cord (colored purple)

    The neurosciences

    In recent years, the neurosciences have increasingly made the leap from a purely basic science to applied research. Despite all this, basic research in south-west Germany is more diverse than ever. The discipline still has a number of breakthroughs to look forward to. The brain remains the most enigmatic human organ and one of the fascinating mysteries of the 21st century.

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/the-neurosciences
  • Press release - 13/06/2024

    BioRegio STERN receives 2024 award for best ZIM innovation network

    BioRegio STERN Management GmbH was today presented with an award at the Innovation Day for SMEs held by Germany’s Federal Ministry for Economic Affairs and Climate Action. Its “biohymed” project was named the year’s best innovation network under the Central Innovation Programme for SMEs (ZIM).

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/bioregio-stern-receives-2024-award-best-zim-innovation-network
  • Press release - 02/07/2024

    DKFZ spin-off Epignostix raises €4.3m seed round to commercialize diagnostic tumor classifier

    Heidelberg Epignostix GmbH, a deeptech start-up committed to precision cancer diagnostics today announces €4.3M in seed funding. This investment will enable Heidelberg Epignostix to make a substantial leap forward in driving market development for its flagship indication for brain tumor classification.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/dkfz-spin-epignostix-raises-euro-43m-seed-round-commercialize-diagnostic-tumor-classifier
  • Press release - 02/02/2024

    University of Stuttgart successful with cluster draft proposals

    The German Research Foundation (DFG) has announced the first pivotal decisions for the "Clusters of Excellence" funding line as part of the Excellence Strategy of the German federal and state governments. The University of Stuttgart has been given the green light for two new cluster initiatives.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/universitaet-stuttgart-mit-clusterskizzen-erfolgreich
  • Press release - 09/07/2025

    A new drug target for treating cancer and viral infections

    An international team of researchers led by Konstanz biologists has identified a molecular mechanism that regulates the activity of N-myristoyltransferases. This enzyme plays a role in biological signalling pathways, where dysregulation can lead to serious illness.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-drug-target-treating-cancer-and-viral-infections
  • Expert interview - 16/12/2024 Man sieht Ventilatorflügel sowie Teile eines Eulenflügels nebeneinander.

    Learning from Nature for Innovation

    Natural phenomena are used to find technological solutions in a number of fields. In an interview with BIOPRO, Prof. Dr. Peter M. Kunz discusses groundbreaking innovations emerging from Baden-Württemberg and shares insights on how the principles of bionics can inspire the next generation of innovators.

    https://www.gesundheitsindustrie-bw.de/en/article/news/learning-nature-innovation
  • Nanoparticles as drug carriers - 09/11/2023 Zu sehen ist eine Mikroskopie-Aufnahme, die mit Mykobakterien infiziertes Lungengewebe inklusive Nanocarrier zeigt.

    Inhalation of nanocarriers for antibiotics against resistant tuberculosis pathogens

    Around ten million people worldwide still contract tuberculosis every year. With an estimated 1.4 million deaths a year, tuberculosis was the world’s deadliest infectious disease until COVID-19. The high mortality rate is down to the sophisticated biology of the pathogen Mycobacterium tuberculosis. A team of researchers from the KIT and the Research Centre Borstel (FZB) has developed a method that aims to outsmart the bacterium once and for all.

    https://www.gesundheitsindustrie-bw.de/en/article/news/inhalation-nanocarriers-antibiotics-against-resistant-tuberculosis-pathogens
  • Elastin as artificial muscle material - 02/03/2022 A small rectangular piece of protein consisting of a beige and a brown layer in a metal container that bends to one side in one picture and to the other side in a second picture.

    Artificial muscle from proteins for diverse future applications

    As far as diversity and complexity are concerned, proteins are nature's smallest marvels. Biotechnologists have already used natural proteins as a basis for the development, bespoke design and production of artificial systems. This is what the livMatS cluster of excellence at the University of Freiburg has been doing. Researchers in the cluster have successfully produced an artificial muscle from elastin that functions autonomously.

    https://www.gesundheitsindustrie-bw.de/en/article/news/artificial-muscle-proteins-diverse-future-applications

Page 3 / 5

sb_search.block.search_result.other.pages

  • eine Seite vor
  • 1
  • 2
  • 3
  • 4
  • 5
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • MDR & IVDR
    • Innovation & Startups
  • Portals
    • BIOPRO BW
    • Healthcare industry
  • To top

stay informed

Newsletter abonnieren

Social Media

  • Xing Xing
  • Twitter visit Twitter
  • LinkedIn visit LinkedIn
  • Rss visit RSS
  • Privacy statement
  • Accessability Declaration
  • Legal notice
  • Sitemap
  • Contact
© 2026
Website address: https://www.gesundheitsindustrie-bw.de/en/search